AptarGroup ATR 深 沪
等待开盘 11-11 09:30:00 美东时间
144.265
+0.135
+0.09%
华盛通- 最 高145.22
- 今 开143.17
- 成交量 26.07万股
- 最 低 141.48
- 昨 收 144.13
- 总市值 914.48万
- 52周最高 148.63
- 市盈率 静 24.53
- 换手率 0.41%
- 52周最低 110.47
- 委 比 77.60%
- 总股本 6.34万
- 历史最高 174.76
- 量 比 0.44
- 振 幅 2.59%
- 历史最低 23.911
- 每 手 1
- 风险率 7.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AptarGroup, Inc. (NYSE: ATR)
NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AptarGroup, Inc. (NYSE: ATR) on behalf of the company's shareholders. The investigation see...
今天 00:34
电话会总结 ｜ Aptar(ATR)2026财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• # AptarGroup 2026财年第三季度业绩回顾摘要 ## 1. 财务业绩 **营收表现：** - 报告销售额达10.2亿美元（刚超10亿美元），同比增长6%，三大业务板块均实现增长 - 核心销售额（剔除汇率及并购影响）同比增长5%，主要由产品组合需求强劲及投入成本转嫁推动 **分部门核心销售额：** - 制药（Pharma）：核心销售额同比增长1%；若剔除6500万美元急救药品（纳洛酮）去库存的全年影响，则增长8% - 处方药：同比下降7%；剔除急救药品后增长6% - 消费者健康：同比增长13%（鼻腔减充血剂和皮肤解决方案需求强劲）
11-01 12:43
财报速睇 | AptarGroup 2026财年Q3营收10.19亿美元，同比增长6.0%；归母净利润0.33亿美元，同比下滑74.5%
华盛资讯10月30日讯，AptarGroup公布2026财年Q3业绩，公司Q3营收10.19亿美元，同比增长6.0%，归母净利润0.33亿美元，同比下滑74.5%。
10-30 22:17
AptarGroup Sees Q4 Adj EPS $1.39-$1.47 vs $1.41 Est
AptarGroup (NYSE:ATR) is looking for Q4 Adj EPS of $1.39-$1.47 vs $1.41 analyst estimate..
10-30 05:20
财报速睇 | AptarGroup 2026财年Q3营收10.19亿美元，同比增长6.0%；归母净利润0.33亿美元，同比下滑74.5%
华盛资讯10月30日讯，AptarGroup公布2026财年Q3业绩，公司Q3营收10.19亿美元，同比增长6.0%，归母净利润0.33亿美元，同比下滑74.5%。
10-30 05:16
AptarGroup To Acquire PULMOTREE, A Munich, Germany-based Life Science Company Specializing In Pulmonary Drug Delivery Systems For Targeted Delivery To The Lungs; Terms Not Disclosed
Acquisition is expected to accelerate development and commercialization of Kolibri™ and expand Aptar Pharma’s respiratory drug delivery platform Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the strategic acquisition of PULMOTREE, a Mun...
10-27 05:01
AptarGroup's Aptar Pharma Reveals CE Marking For LuerVax
Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax® intranasal delivery device and accompanying Spray Divider have been CE marked under the EU Medical Device Regula...
10-15 05:05
美股大行评级 | 潜在涨幅91.5%！巴克莱上调Vertical Aerospace评级至"标配"，目标价下调至1美元
今日重点评级关注：巴克莱：上调Vertical Aerospace评级至"标配"，目标价从2美元降至1美元；巴克莱：维持Bitdeer Technologies"超配"评级，目标价从15美元升至17美元
10-12 14:52
UBS Initiates Coverage On AptarGroup with Neutral Rating, Announces Price Target of $135
UBS analyst Anojja Shah initiates coverage on AptarGroup (NYSE:ATR) with a Neutral rating and announces Price Target of $135.
10-09 23:15
AptarGroup’s Russian Subsidiary Placed Under Temporary External Administration By Kremlin Decree; Says Aptar Vladimir Represented Less Than 0.6% Of Net Sales And Operating Income As Of Dec 31, 2025
AptarGroup, Inc. (the "Company") takes note of the decree of the President of the Russian Federation, published on September 21, 2026, that places the Company’s Russian subsidiary, OOO Aptar Vladimir ("Aptar Vladimir"), under temporary external administration. The Company is assessing the situation ...
09-22 05:19
